X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TERN-501 is a thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development for the treatment of NASH.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
TERN-501 is a thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
TERN-101 demonstrates a differentiated safety and efficacy profile, including the potential to decrease liver inflammation and fibrosis as measured by cT1, an increasingly recognized non-invasive biomarker of fibro-inflammation.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2021
Details:
TERN-101, a farnesoid X receptor agonist, with enhanced liver distribution being developed for the treatment of NASH. TERN-101 is used as monotherapty and co-administered with TERN-501.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
The LIFT study is a parallel-group, Phase 2a clinical trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of orally-administered TERN-101 tablets at doses of 5 mg, 10 mg and 15 mg in 100 adult patients with presumed NASH.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
TERN-101 is a liver-distributed, non-bile acid FXR agonist that has demonstrated a differentiated tolerability profile and improved target engagement, likely due to its sustained FXR activation in the liver but only transient FXR activation in the intestine.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
Terns Pharmaceuticals has completed patient enrollment in the LIFT study, a Phase 2a NASH clinical trial of TERN-101, a liver-distributed non-bile acid farnesoid X receptor agonist that has shown differentiated tolerability profile and improved target engagement in the liver.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
At the upcoming Annual AASLD meeting, Terns Pharmaceuticals will present data from across its diverse NASH pipeline, including the first preclinical evidence supporting the rationale for combining TERN-101, currently in Phase 2 studies, and TERN-501.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
Trial is evaluating the safety and efficacy of farnesoid X receptor (FXR) agonist TERN-101 in NASH patients.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
Terns Pharmaceuticals has screened the first patient for the LIFT study, a Phase 2a clinical trial of TERN-101, a liver-selective farnesoid X receptor (FXR) agonist, the company's lead development candidate for the treatment of non-alcoholic steatohepatitis (NASH).
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
Phase 1 study demonstrated TERN-101 is safe and exhibits potent target engagement at all dose levels studied.
Lead Product(s): TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
